Ann: Osteopore gains access to Switzerland, page-3

This stock really is a trader's delight (+100%!!).

For investors its a tightrope walk between the very promising science being advanced in regulatory and academic partnership, vs atrocious past financial management and disregard for shareholders and natural share price/capital value fears that emerge from that atrocious history.

As an investor I am obviously hopeful of success with a massive dose of reality in the risks of this management getting there commercially. Massive likely share price reward if they get there, versus the simple risk of going to zero. Not an investment for the feint hearted....